Drugs /

azd5069

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.

Clinical Trials

View Clinical Trials for azd5069

Azd5069 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating azd5069, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).

Hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, and malignant solid tumor are the most common diseases being investigated in azd5069 clinical trials [2].

Drug Details

Synonyms [2]:
cxcr2 antagonist azd5069, cxc chemokine receptor 2 antagonist azd5069, cxcr2 antagonist azd5069
Drug Target(s) [2]:
CXCR2
NCIT ID [1]:
C123383

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.